A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

This study is testing a combination of four drugs — mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide — in people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. **You may be eligible if...** - You are 18 or older with relapsed (returned) follicular lymphoma (grades 1–3a) or diffuse large B-cell lymphoma that expresses the CD20 protein - Your lymphoma has progressed or failed to respond after at least one prior treatment - You have at least one measurable tumor site greater than 1.5 cm - Your blood counts and organ function meet the required minimums **You may NOT be eligible if...** - Your lymphoma is a different subtype not covered by this study - You have not received any prior treatment for your lymphoma - Your blood counts or organ function are too low - You have serious uncontrolled health conditions that would make the treatment unsafe Talk to your doctor to see if this trial is right for you.